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Background: Due to common evolutionary origins, mitochondrial DNA (mtDNA) shares many 
similarities with immunogenic bacterial DNA. MtDNA is recognised as a pro-inflammatory 
damage-associated molecular pattern (DAMP) with a pathogenic role in several inflammatory 
diseases. We hypothesised that mtDNA is released during active disease serving as a key 
pro-inflammatory factor in IBD. 
 
Methods: Between 2014-2015, we collected plasma separated within 2 hours of sampling 
from 97 prospectively recruited IBD patients (67 ulcerative colitis [UC] and 30 Crohn’s disease 
[CD]), and 40 non-IBD controls. We measured circulating mtDNA using qPCR (amplifying 
mitochondria COXIII/ND2 genes) and also in mouse colitis induced by dextran sulfate-sodium 
(DSS). We used mass spectometry approach to detect free plasma mitochondrial formylated 
peptides. Furthermore, we examined for mitochondrial damage using electron microscopy 
(EM) and TLR9 expression, the target for mtDNA respectively, in human intestinal IBD 
mucosa. 
 
Results: Plasma mtDNA levels were increased in UC and CD (both p<0.0001) compared to 
non-IBD controls. These levels were significantly correlated to blood (CRP, albumin, white cell 
count), clinical and endoscopic markers of severity; and disease activity. In active UC, we 
identified 5 mitochondrial formylated peptides (the most abundant, fMMYALF with known 
chemoattractant function) in plasma. We observed mitochondrial damage in inflamed UC 
mucosa and significantly higher fecal MtDNA levels (vs. non-IBD controls [p<0.0001]), which 
support gut mucosal mitochondrial DAMP release as primary source. In parallel, plasma 
mtDNA levels increased during induction of acute DSS colitis and were associated with more 
severe colitis (p<0.05). In active IBD, TLR9+ lamina propria inflammatory cells were 
significantly higher in UC and CD compared to controls (p<0.05). 
 
Conclusions: We present the first evidence to show that mtDNA is released during active 
IBD. MtDNA is a potential mechanistic biomarker and our data point to mtDNA-TLR9 as a 
therapeutic target in IBD. 
 
Keywords: Mitochondrial DNA, DAMPs, TLR9. 
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INTRODUCTION 
The most widely accepted hypothesis underpinning the aetiology of Crohn’s disease (CD) and 
ulcerative colitis (UC) involves four pathogenic components: a dysregulated immune 
response, genetic susceptibility, abnormal microbial composition and environmental triggers1. 
There are clear differences between CD and UC. However, failure to resolve mucosal 
inflammation (which commonly reactivates upon withdrawal of anti-inflammatory treatments) 
is a notable shared clinical feature. In 1994, the “danger hypothesis” was proposed, in which 
immune responses are geared toward recognizing danger, irrespective of whether these 
signals arise endogenously or exogenously2. Endogenous damage-associated molecular 
patterns (DAMPs) are ‘danger signals’ or ‘alarmins’ released during host cellular stress or 
injury. Along with exogenous pattern associated molecular patterns (PAMPs) of microbial 
origins, DAMPs can initiate and perpetuate an inflammatory response typically via germline 
encoded pattern recognition receptors (PRR). We (and others) have recently suggested that 
DAMPs represent underexplored but potentially important pathogenic stimuli that maintain the 
state of abnormal mucosal inflammation in inflammatory bowel disease (IBD)3.  
 
We recently showed that gut mitochondrial dysfunction can result in loss of epithelial barrier 
function and the development of colitis4. In this study, we focus on mitochondria as a source 
of DAMPs in IBD. Mitochondria are intracellular double-membrane-bound organelles with 
many essential physiological roles such as energy production, regulation of cell death and 
immune responses5. Mitochondria are evolutionarily derived from energy-producing alpha-
bacteria, engulfed by archezoan cells approximately 2 billion years ago leading to a symbiotic 
relationship that forms the basis of the eukaryotic cells6. As such, mitochondria share several 
features with their bacterial ancestors, notably with a double-membrane structure and an 
independently replicating genome rich in hypomethylated CpG motifs, very similar to bacterial 
DNA. Just as the innate immune system recognizes conserved bacterial molecules, 
mitochondrial constituents are similarly immunogenic, acting as DAMPs during their 
uncontrolled release7.  
 
The mitochondrial DAMP which has thus far attracted the most attention is mitochondrial DNA 
(mtDNA). Collins et al, first reported the inflammatory potential of mtDNA in 2004, when they 
found that mtDNA (and not nuclear DNA) induced TNFα and caused inflammatory arthritis 
when injected into the joints of the mice8. MtDNA activates multiple pathways, notably toll-like 
receptor (TLR)-9 when it is released extracellularly, as well as the cytosolic NLRP3-
inflammasome and STING pathways7. It is proposed that extracellular mtDNA mainly (but not 
exclusively) mediates its pro-inflammatory action via TLR9 which then proceeds through 
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MyD88 triggering MAPK- and NFκβ-signalling9, or through interferon regulatory factor 7 (IRF7) 
to enhance type 1 interferon response in dendritic (DC) or other immune cells. Uncontrolled 
mtDNA release is evident during conditions associated with acute tissue injury such as 
systemic inflammatory response syndrome (SIRS), fulminant liver failure and sepsis9-11; and 
in chronic inflammatory states such as systemic lupus erythematosus (SLE)12. Given the 
significant tissue injury burden typically observed in active IBD, we hypothesised that such 
pathogenic release is present and that mtDNA can act as a pro-inflammatory DAMP 
potentiating and perpetuating the abnormal inflammatory response.  
 
MATERIAL AND METHODS 
IBD and control cohorts 
Individuals were recruited from outpatient and inpatient settings from the Gastrointestinal Unit, 
Western General Hospital, Edinburgh between April 2014 and November 2015. For the IBD 
cohort, recruited patients fulfilled the Lennard-Jones criteria of CD or UC13. IBD patients were 
classified into CD or UC based on clinical, endoscopic and histologic criteria. In addition, 
individuals with irritable bowel syndrome (IBS) or with no history of IBD and no GI symptoms 
were recruited as non-IBD controls. IBS individuals had altered bowel habit and were defined 
following normal ileo-colonoscopy, stool calprotectin and blood parameters. Individuals were 
excluded if they were younger than 18 or were unable to give written consent. Individuals with 
indeterminate colitis and non-IBD colitis (e.g. infective and microscopic) were excluded. 
 
Biological material from subsets of prospectively recruited patients were used for: 
1. Faecal mtDNA analysis (n=12 active UC vs. 12 non-IBD controls) 
2. Mass spectrometry analysis (n=5 acute severe UC vs. 5 non-IBD controls) 
3. Electron microscopy (n=6 active UC vs. 6 non-IBD controls) 
4. UC patients with longitudinal plasma sampling pre- and post-colectomy (n= 9). 
 
All clinical and biological material/data acquisition were carried out under Lothian Bioresource 
ethics approval 15/ES/0094.  
 
Clinical phenotype: Disease activity 
For UC and CD, disease activity was classified using the Simple Colitis Clinical Activity Index 
(SCCAI) and Harvey Bradshaw Index (HBI) respectively. Clinical remission was defined as 
SCCAI of less than or equal to 2 for ambulatory ulcerative colitis patients, and HBI of less than 
5 for ambulatory patients with Crohn’s disease. “Ambulatory” patients were defined as 
outpatients. Inpatients were further classified into acute severe disease if they required 
intravenous steroids for CD or fulfilling the Truelove & Witts criteria for UC. Endoscopic 
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assessment of disease severity was obtained from endoscopic reports generated by GI 
physicians in charged of patients at time of sample collection. Further clinical (stool frequency, 
temperature and pulse) and disease severity characteristics including labarotory assessments 
(FBC, C-reactive protein and serum albumin) were collected at the time of recruitment and 
blood sampling. 
 
Human plasma processing 
Venepuncture was performed by a trained clinician with a 21 gauge butterfly needle. 12-18mL 
of blood including at least 9mL in an ethylenediaminetetraacetic acid tube (Vacuette ®) was 
collected and processed within 2 hours. EDTA blood was centrifuged at 1000g for 10 minutes 
at 4oC and the plasma fraction was transferred to a 15mL Falcon ® tube; this was then 
centrifuged at 5000g for 10 minutes at 4oC to remove platelets and microparticals, and achieve 
‘cell free plasma’. Plasma was divided into 0.5mL aliquots and stored at -80oC until further 
use. 
 
Extraction of mtDNA from plasma 
DNA was isolated using the QIAamp DNA Blood Mini Kit as per manufacturer’s instructions14. 
200μl of plasma was used for each sample. Purity of the DNA was determined using Nanodrop 
2000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and all DNA samples had 
OD260/OD280 values of 1.7-2.0.   
 
Stool processing 
DNA was isolated using the QIAamp DNA Stool Mini Kit as per manufacturer’s instructions. 
To minimise cellular disruption (and thus minimise processing-related liberation of DAMPs), 
phosphate buffered saline (PBS) was used instead of Buffer ASL in step 2 of the protocol.  
 
qPCR protocols 
Creation of Standard Curves 
Standard curves for absolute quantification of circulating free mtDNA were developed using a 
modified protocol of that described previously14. Mitochondria were extracted from cultured 
HepG2 cells using the Sigma Mitochondrial Isolation kit for cultured cells using the 
manufacturer’s instructions. Isolated mitochondria were stored at -20oC until further use. DNA 
was extracted using the QIAamp DNA Micro Kit (Qiagen, Valencia CA, USA) as per the 
manufacturer’s instructions. Primer sequences (cytochrome C oxidase subunit III (COXIII): 
forward ATGACCCACCAATCACATGC, reverse ATCACATGGCTAGGCCGGAG; NADH-
dehydrogenase 2 (ND2): forward CACAGAAGCTGCCATCAAGTA; reverse 
CCGGAGAGTATATTGTTGAAGAG) were blasted against human genome as well as known 
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bacteria in order to ensure selectivity for human mtDNA 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  
 
mtDNA primer products were amplified by conventional PCR. PCR conditions were Stage 1 - 
95oC for 2 minutes; Stage 2 - 40 cycles of 95oC for 30 seconds, 58oC for 30 seconds; Stage 3 
- 72oC for 5 minutes. The PCR product was then run on a 4% agarose gel (2g of agarose 
resuspended in 50ml 1x TBE  with 5μl Gel Red added to the solution once the agarose 
dissolved). 10μl of PCR product used and samples run next to a 100bp DNA ladder. PCR 
product size was as expected (103bp for COXIII, 90bp for ND2). A QIAgen PCR Purification 
kit was used in accordance with manufacturer’s instructions. The DNA was then eluted with 
50μl Buffer EB into a sterile 1.5ml Eppendorf and stored at -20°C until use. Isolated DNA was 
quantified by nanodrop (ThermoScientific). Standards were created from serial 10 fold 
dilutions of the PCR primer product. 
 
Absolute Quantification 
Primers (MWG Eurofins) were suspended at 100μM stock solution with DEPC-treated water 
and stored at -20°C prior to use.  Subsequently, 20x primer solution (1.8μM) was made (3.6μL 
forward, 3.6μL reverse, 192.8μL DEPC-H2O).  In MicroAmp® Optical 384-Well Reaction 
Plates (Applied Biosytems) 7μl of master mix containing 5μL 2x SYBR Green Fast mix 
(Applied Biosystems), 0.5μL 20x primer mix and 1.5μl DEPC-treated water was mixed with 
3μl of isolated DNA sample or standard.  All reactions were carried out in duplicate, and 
discordant results retested. All plates contained wells with no DNA as a negative, no template 
control.  qPCR reactions were conducted in an ABI7900 Fast Real-Time PCR System (Applied 
Biosystems) with the following settings: Stage 1 - 95°C for 20 sec; Stage 2 - 40 cycles of 95°C 
for 3 sec & 60°C for 30 sec; Melt curve: 95°C for 15 sec, 60°C for 1 min, 95°C for 15 sec, 60°C 
for 15 sec. Absolute quantification of mtDNA was determined relative to the standard curve 
based on the following equation (as described by Chiu et al 14):  
 
C = Q x VDNA/QPCR x 1/Vext 
x C   target concentration in plasma or serum (copies per millilitre);  
x Q   target quantity (copies) determined by sequence detector in PCR;  
x VDNA  total volume of DNA obtained after extraction, typically 50μl per extraction; 
x VPCR  volume of DNA solution used for PCR, typically 3μl  
x Vext  volume of plasma, typically 200μl 
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Amplification efficiency of between 90 and 110% was taken as acceptable where slope refers 
to the gradient of the standard curve: (Efficiency = 10(-1/slope) – 1). The coefficient of 
determination value was also calculated with r2>0.985.  Meltcurves were run to identify the 
presence of a primer dimer peak. 
 
Mass Spectrometry 
Plasma samples (100μL) were acetone precipitated, dried down under vacuum and 
reconstituted in 0.5% acetic acid. Peptides were then analysed by LC-MS/MS in positive ion 
mode using a Thermo LTQ-Orbitrap XL mass spectrometer (Hemel Hempstead, UK) coupled 
to a Waters nanoAcquity UPLC system (Manchester, UK) with a linear gradient over 39 min 
(mobile phase A: 0.5% acetic acid in water; mobile phase B: 0.5% acetic acid in acetonitrile). 
N-formylated hexapeptides were identified on the basis of their accurate mass, retention times 
and characteristic fragmentation patterns compared to custom synthesised standards 
(Peptide Protein Research Ltd, Fareham, UK). Quantification was achieved using a 
corresponding stable isotope labelled internal standard and calibration curve for each N-
formylated hexapeptide. 
 
Mouse experiments and induction of colitis  
C57/BL6 wild-type were used in experiments carried out under Home Office Project Licence 
PPL 70/8847 (Dr G-T.Ho). Acute colitis was induced by 2% DSS (MP Biomedicals Ltd) in 
drinking water ad libitum for 7 days. Mice were monitored daily for weights, presence of 
diarrhoea and blood. Euthanasia was performed using CO2 and blood collection was carried 
using direct cardiac puncture (~500ul) into EDTA eppendorfs. Like human plasma processing, 
EDTA blood was centrifuged at 1000g for 10 minutes at 4oC and the plasma fraction was 
transferred further centrifuged at 5000g for 10 minutes at 4oC to remove platelets and 
microparticles. 
 
Transmission Electron Microscopy 
Colonic pinch biopsies from IBD and non-IBD individuals were obtained from distal colon 
during colonoscopy, briefly washed with sterile PBS and immediately transferred into 3% EM 
grade glutaraldehyde solution in 0.1M Sodium Cacodylate buffer, pH 7.3, for 2 hours before 
further processing (details available on request). For mouse studies, colons were flushed with 
PBS before transfer into EM solution as above. All TEMs were carried out at Electron 
Microscopy Unit, King’s Building, University of Edinburgh. 
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Immunohistochemistry 
Immunohistochemistry for anti-TLR9 (1 in 50 following Tri-EDTA antigen retrieval; Abcam 
ab52967) were performed on pseudo-anonymised human IBD and non-IBD colonic resection 
samples provided by pathology department (Dr J-L) using the Scottish Tissue Bank via 
Scottish Academic Health Sciences Collaboration (SAHSC) SR493. All IBD samples were 
coded and matched (sex, age and tissue location) with a non-IBD control group. 
 
Statistical analysis 
Data are presented as numbers, percentages, means±SEM and medians±IQR for parametric 
and non-parametric data respectively. Student t- and Mann-Whitney statistics were used for 
parametric and non-parametric data respectively. Receiver operating characteristic (ROC) 
analyses were carried out using paramaters: mtDNA, C-reactive protein and albumin levels to 
predict need for colectomy. Multivariate logistic regression were performed to assess variables 
predictive of high mtDNA. Wilcoxon matched-pairs signed rank test was used to determine 
the difference in matched pre- and post-colectomy mtDNA levels. Spearman’s correlations 
were calculated to evaluate the relationship between mtDNA level and other biochemistry, and 
between COXIII and ND2 qPCR results. Statistical analyses were performed using Graphpad 
version 7 (Graphpad Software, San Diego, California, USA) and SPSS version 22 (IBM Corp., 
Chicago, USA). Two-sided p values of <0.05 were considered statistically significant. 
 
RESULTS 
Increased circulating plasma mtDNA in UC and CD  
We prospectively recruited and collected plasma from 97 IBD patients (67 UC and 30 CD 
patients), and 40 non-IBD controls (20 healthy [HC] and 20 irritable bowel syndrome [IBS] 
controls) (Table 1). In all our samples, we performed qPCR using 2 sets of primers flanking 
COXIII and ND2 genes of the mitochondrial genome. COXIII and ND2 data were highly 
correlated (r=0.84; p<0.0001)(Supplementary Figure 1) and COXIII data indicative of mtDNA 
release is presented from hereon. Overall, we found significantly higher levels of circulating 
cell-free plasma mtDNA in IBD (167.8 copies/μl [interquartile range, IQR 78.06-387.2]) 
compared to HC (64.6 copies/μl [IQR 51.6-104]) (p=0.0002) and IBS (44.6 copies/μl [IQR 27.9-
134.7]) (p<0.0001). There was no difference between HC and IBS, and these groups were 
combined as non-IBD controls (Figure 1A). Plasma mtDNA levels were significantly higher in 
both UC (172.3 copies/μl [IQR 74.4-393.2]) (p<0.0001) and CD (136.7 copies/μl [IQR 88.0-
370.9]) (p<0.0001) compared to non-IBD controls (61.5 copies/μl [IQR 32.8-104])  (Figure 
1B).  
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In UC, individuals with acute severe disease as defined by Truelove and Witts criteria and 
severe endoscopic appearances, have the highest mtDNA levels (Figure 2A and B): clinical 
remission (53.77 copies/μl [IQR 30.56 – 86.8] vs. severe UC (234.7 copies/μl [115.3 – 723.4]) 
(p<0.0001); and endoscopically mild (33.11 copies/μl [IQR 28.71 – 44.9] vs. severe UC (255.4 
copies/μl [96.71 – 641.4]) (p<0.001). In the smaller cohort of CD, higher mtDNA levels were 
observed in those with severely active CD (159.1 copies/μl [IQR 90.17-421]) compared to 
those in remission(79.92 copies/μl [IQR 30.94 – 145.9] (p=0.04) (Figure 2C). In acute severe 
UC who were hospitalised, mtDNA levels on admission in patients who went on to require 
subsequent emergency colectomy were higher than those who responded to medical therapy 
(colectomy: 302.5 copies/μl [IQR 139 – 1553] vs no colectomy group 165 copies/μl [66.75 – 
253]; p=0.04). Comparative ROC analysis of mtDNA, C-reactive protein and albumin 
demonstrated an area under curve (AUC) of 0.71, 0.76 and 0.82 in predicting colectomy 
(p=0.04, 0.01 and 0.002) respectively (Supplementary Figure 2). In CD, only one individual 
had surgery during recruitment, hence similar analyses were not performed. In our overall IBD 
cohort, we found that mtDNA levels were significantly correlated with severe disease markers 
C-reactive protein (r=0.33, p<0.0001), albumin (r=-0.32, p<0.0001), and white cell count  
(r=0.37, p<0.0001) (Supplementary Figure 3). We identified a group of individuals with very 
high mtDNA levels (n=18, >600 copies/μl) and investigated if there were unique phenotypic 
characteristics that defined the group. Multivariate analysis showed that C-reactive protein 
was independently associated with very high mtDNA levels (p=0.007, Supplementary Table 
1). Collectively, our data show that circulating plasma mtDNA can be detected and are 
significantly increased in UC and CD; and mtDNA levels were associated with disease activity 
and severity. 
 
Mitochondrial N-formylated peptides are also increased in active IBD 
A further shared feature of the mitochondria with bacteria, is the production of short N-
formylated peptides. Bacterial and mitochondrial proteins are the only source of N-formylated 
peptides in nature. Mitochondrial N-formylated peptides are functional similar to their bacterial 
counterparts acting as primarily as neutrophil chemoattractants15. To provide further 
corroborative evidence, we employed a mass spectrometric approach to identify and quantify 
N-mitochondrial formylated peptides in a subset of 5 acute severe UC vs. 5 non-IBD controls. 
A screen for the free N-terminal hexapeptides of the thirteen known mitochondrial encoded 
proteins confirmed the presence of five N-formylated termini (fMMYALF, fMTPMRK, 
fMNPLAQ, fMNFALI and fMTMHTT) in acute severe UC samples. These were not detected 
in non-IBD controls. When quantified with synthentic standards, we found that the 
concentrations of each of these formylated peptides was significantly elevated (p<0.01) in 
acute severe UC (Figure 3). Of the mitochondrial N-formylated peptides, fMMYALF was the 
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most abundant. This is highly relevant as fMMYALF is the most biological active mitochondrial 
N-formylated peptide16.  
 
Increased plasma mitochondrial DNA release in acute DSS colitis 
In order to provide further supportive data, we used the acute dextran sulfate sodium (DSS) 
colitis mouse model to test if plasma mtDNA can be detected as colitis developed. Similar to 
human IBD, we found significantly higher plasma mtDNA following acute DSS colitis (Figure 
4A) and high levels of mtDNA were associated with more severe colitis (>10% vs. <10% 
weight loss at day 7 of DSS colitis; p=0.03) (Figure 4B). These findings in an acute colitis 
model supported our recent findings that also demonstrated increased plasma mtDNA in the 
chronic mdr1a-deficient colitis model4. Hence, these data indicate that gut inflammation is 
associated with the release of mtDNA during active colitis.  
 
Intestinal mucosal mitochondrial damage and mtDNA release in active IBD 
We recently showed that loss of mitochondrial protective mechanism at the intestinal mucosal 
level rendered the mitochondria susceptible to damage, and triggered the onset of colitis in 
multidrug resistant-1 (mdr1) deficient mice4. Other relevant IBD mice models with primary 
autophagy (Irgm and Atg16l1)17,18; including those with secondary autophagy impairments due 
to defective ER-stress19 and NLRP6 inflammasome activity20 all exhibited similar 
accumulations of damaged mitochondria within the gut epithelium as seen in mdr1-deficient 
mice. The findings of abnormal mitochondria have been demonstrated in human IBD21-23. We 
confirmed these when we prospectively sampled pinch biopsies from affected colon in 
individuals with active UC and from non-IBD controls (Supplementary Table 2). Transmission 
EM of the colon showed evidence of mitochondrial damage (with loss of inner cristae structure, 
increased lucency with swollen rounded appearances) in areas of cellular injury and were also 
extravasated within sub-epithelium in affected UC mucosa (n=6/group; active UC vs. non-
IBD). (Figure 5A) (Supplementary Figure 4A and B). The nature of EM did not allow more 
detailed discrimination of whether specific enterocyte or inflammatory cell types displayed a 
predilection towards mitochondrial damage. We hypothesised that mitochondrial DAMPs are 
released primarily from affected IBD mucosa. We prospectively sampled faecal samples from 
individuals with active severe UC and found significantly higher mtDNA levels (p<0.0001) 
compared to non-IBD controls (Figure 5B). Overall, faecal mtDNA were higher than plasma 
levels (~1000-fold) although this maybe explained by inherent nature of the different biological 
material. In a longitudinal series of acute severe UC with paired samples pre- and post-
colectomy (median Δ107 days, IQR 89-189), plasma mtDNA fell to normal following colectomy 
(n=9, p=0.008) (Figure 5C). Many lines of evidence suggest that mtDNA’s DAMP effect is 
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mediated via TLR9, which is expressed in many immune cells including dendritic cells, B-cells 
as well as the intestinal epithelium24. We analyzed TLR9 protein expression in human IBD 
colonic resection specimens and found increased frequency of lamina propria TLR9+ve cells 
in active UC and CD (Figure 6A, B). Collectively, these data suggest that extravasation of 
mtDNA primarily occurs at the inflamed mucosa level in active IBD where TLR9 expression, 
its primary cellular target is increased. Presently, the latter is associative and more work is 
necessary to confirm the downstream effects of mtDNA on gut mucosal immune response. 
Taken together, indicate that mtDNA-TLR9 signalling is an attractive therapeutic target and 
mtDNA itself, may have a role as a mechanistic biomarker. 
 
DISCUSSION 
We present data to show for the first time that significantly increased levels of mtDNA are 
found in active human IBD and in mouse colitis. Furthermore, plasma mtDNA levels correlate 
with disease activity and severity. We corroborated our findings with a second known DAMP, 
by demonstrating the presence of N-formylated peptides arising from the mitochondria in the 
plasma. In this context, we posit that increased mitochondrial damage occur at the inflamed 
IBD mucosa (supported by human and mouse studies); they are released in a pathogenic 
manner (both quantitatively and qualitatively) where they can be detected in the circulation 
and in the stools. Given that many lines of evidence implicate their functional pro-inflammatory 
actions, these findings have direct translational importance.  
 
MtDNA’s role as a TLR9 agonist has received most attention where many inflammatory 
models show better outcomes when TLR9-signalling is abolished. Tlr9–deletion is protective 
against SIRS following systemic administration of mitochondrial DAMPs25; and in lung26, liver27 
and kidney28 injury models characterised by high mtDNA release. Blocking TLR9 using 
inhibitory ligands have been shown to improve mtDNA-driven mouse models of cardiac 
failure29 and non-alcoholic steatohepatitis (NASH)30. The role of mtDNA-TLR9 in IBD and 
intestinal inflammation however, is more complex. TLR9 is expressed both in the epithelium 
and, in resident and recruited lamina propria immune cells. Whereas NFKB-activation is pro-
inflammatory31, intestinal epithelial NFKB-activation is cytoprotective and important to 
maintain barrier integrity32. Hence in tlr9-deficiency, the intestinal epithelium is postulated to 
have lower protective NFKB-activation and is more susceptible to injury. CpG oligonucleotide 
treatment in mouse studies using low dose DSS colitis showed either no difference or a 
protective role with the beneficial effects seen before the induction of colitis 33-35. Furthermore, 
CpG oligonucleotide treatment given during colitis worsened inflammation36.  A recent clinical 
study on TLR9-agonist in moderate-to-severe UC failed to show overall clinical improvement37. 
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Hence, translating anti-TLR9 therapy in IBD is likely dependent on the stage of inflammation 
and the cellular context of where TLR9 is blocked.   
 
Our data show a promising future role for mtDNA (and DAMPs) as a mechanistic biomarker. 
We recently highlighted the importance of such biomarkers to identify sub-mechanisms that 
drive the heteregenous clinical presentations and disease progression in IBD, where specific 
therapeutic interventions can be stratified accordingly. Clearly, more detailed studies are 
necessary to fully test mtDNA’s utility as a biomarker. There are limitations to our current data. 
First, we have not studied mtDNA in non-IBD intestinal inflammatory conditions such as 
infectious colitis or diverticulitis. It is conceivable that high mtDNA release is also present. 
Second, our cohort was predominantly individuals with active UC (data for mitochondrial 
formylated peptides, EM and faecal mtDNA were drawn from this group). It is not clear if similar 
findings are found in CD. It would be of interest, to study a wider cohort of gut inflammatory 
conditions to determine whether mtDNA data is more specific for IBD or if it is a general marker 
for gut inflammation (like calprotectin). 
  
The are many translational opportunities offered by targeting mitochondrial DAMPs. These 
includes inhibiting mtDNA release (e.g. diverting the manner of cellular death or active 
extrusion of mitochondrial DNA using pro-apoptotic caspases), reducing the inflammatory 
potential of mtDNA (e.g. mitochondrial anti-oxidant treatment or DNAases to disgest NET-
bound mtDNA), augmenting damaged mitochondrial clearance mechanisms (e.g. mitophagy 
activation), interfering with mtDNA-TLR9 activation (using inhibitory CpG ligands) and 
targeting downstream NFKB- and MAPK-pathways in the relevant inflammatory cell groups 
(e.g. neutrophils) (reviewed in38). Similarly, much is known about the biological effects of N-
formylated peptides and its cognate receptors (FPR1, 2 and 3). Activation of FPR1 drives 
neutrophil chemotaxis and stimulates a variety of antimicrobial responses, including 
degranulation, reactive oxygen species production and cytokine release. We recently show 
that both FPR1 gene-deletion and pharmacologic inhibition are protective in inflammatory lung 
disease6.39,40. There are other DAMPs such as calprotectin (s100a8/9), high mobility group 
box-1 (HMGB1) and interleukin (IL)-33  (reviewed in3) with known pro-inflammatory 
mechanisms found in active IBD. The relative importance of these DAMPs is not yet clarified 
but as it stands, offers a rich ream of further translational opportunities. 
 
In conclusion, our study suggests that mtDNA acts as a DAMP promoting inflammation in IBD. 
More broadly, our findings open up a new mechanistic layer and further expands the current 
model of IBD pathogenesis to incorporate the ‘danger’ model. Hence DAMPs as ‘enemies 
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within’, represents a potential major player in addition to established data implicating genetic 
susceptibility, and exogenous microbial and environmental factors in the pathogenesis of IBD. 
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Figure 1A: Plasma mtDNA (copy/μl) in IBD, HC and IBS (n= 97, 20 and 20 samples 
respectively; p=<0.001); B: Plasma mtDNA (copy/μl) in CD, UC and non-IBD (n= 30, 67 and 
40 samples respectively). Median±Interquartile Range (IQR). 
 
Figure 2A: Plasma mtDNA (copy/μl) in UC in clinical remission (ambulatory), active 
(ambulatory) and severe active (hospitalized) (n= 13, 18 and 44 samples respectively; 8 UC 
individuals had samples taken more than 1 time point during active disease and in remission); 
B: Categorised according to mild, moderate and severe endoscopic appearances (n= 4, 41 
and 23 samples espectively). C: Plasma mtDNA(copy/μl) in CD, clinical remission 
(ambulatory), active (ambulatory) and severe disease (hospitalized) (n= 10, 5 and 16 samples 
respectively. One CD individual had samples taken more than 1 time point during active 
disease and in remission).  
 
Figure 3: Mitochondrial formylated peptide quantification in 5 UC vs. 5 non-IBD controls  
(*p=<0.01 for fMMYALF, fMTPMRK, fMNPLAQ, fMNFALI and fMTMHTT).Mean±Standard 
Error of Mean 
 
Figure 4A: Plasma mtDNA (copies/ml) following acute DSS colitis vs. controls (n= 12 and 
14, p=0.01)†. B: Plasma mtDNA (copies/ml) stratified to < or >10% weight loss at Day 7 of 
DSS colitis (p=0.03). Median±Interquartile Range (IQR) 
 
Figure 5A: Representative transmission electron microscopy of distal colonic epithelium 
from active UC vs. non-IBD controls (n= 6/group; bar = 5μm). Annotated image: Purple – 
damage mitochondria (DM), Blue – healthy mitochondria (HM) and yellow – lipid droplets 
(LD). Black scale bar 2μm. Yellow insert – Damaged and healthy mitochondria from UC and 
controls respectively (Orange bar 0.5 μm); B: Faecal mtDNA (copy/ml) in active UC and 
non-IBD controls (n=12/group). C: Longitudinal analysis of plasma mtDNA(copy/μl) in UC 
(n=9 patients) during active disease and the same patient post colectomy in clinical 
remission. All data represent median ± IQR. 
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Figure 6A: Immunohistochemistry for anti-TLR9 in human IBD colon (UC and CD; 
n=7/group vs. non-IBD control; n=14). Red arrows – TLR9 positive cells. Black scale bar 100 
μm. B: TLR9+ve cell counts in lamina propria (LP) of human IBD colon per 2mm2 (UC and 
CD; n=7/group vs. non-IBD control; n=14)‡. Mean±Standard Error of Mean. 
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Table 1: Baseline characteristics of IBD and controls. IBD – Inflammatory bowel disease, CD 
– Crohn’s disease, UC – Ulcerative colitis, HC – Healthy controls and IBS – Irritable Bowel 
Syndrome. Data presented as median (±IQR).  
 IBD Controls 
 CD UC HC IBS 
n 30 67 20 20 
Age 37 (27-44) 36 (28-51) 36 (32-46) 33 (27-42) 
M / F 17 / 13 44 / 23 10 / 10 13 / 7 
Current smoker 26% 21% 15% 25% 
Crohn’s Disease 
 Clinical Remission & 
Ambulatory 
Clinically Active & 
Ambulatory 
Hospitalized (IV 
Steroids) 
Hb (g/dl) 145 (137-151) 156 (138-158) 130 (125-137) 
WCC (x109/L) 7.4 (5.4-15.1) 10.9 (7.7-11.9) 8.75 (7.4-11.6) 
Platelets (x109/L) 253 (218-295) 509 (300-414) 334 (279-378) 
C-reactive protein 3.5 (1-7.5) 5 (3.5-8) 26 (12-62) 
Albumin 38 (33-40) 38 (37-38) 29 (27-34) 
HBI 1 (0-2) 7 (6-9) 7 (4-14) 
Ulcerative Colitis 
 Clinical Remission & 
Ambulatory 
Clinically Active & 
Ambulatory 
Hospitalized (IV 
Steroids) 
Hb (g/dl) 136 (128-151) 131 (123-146) 114 (104-130) 
WCC (x109/L) 6.3 (4.7-7.5) 7.7 (6.3-8.8) 11.3 (8.3-14.6) 
Platelets (x109/L) 292 (252-303) 305 (256-335) 414 (288-501) 
C-reactive protein 2 (2-5) 3 (2-17) 21 (10-54) 
Albumin 39 (38-40) 38 (35-40) 30 (25-34) 
SCCAI 0 (0-0) 6 (4-8) 7 (4-10) 
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 Supplementary Table 1 – Multivariate logistic regression to analyse parameters associated 
with high mtDNA levels in 160 samples with complete paired data with mtDNA levels 
(mtDNA >600 vs. ≤600 copies/μL). 
 p-value 95% CI for Exp (B) 
Hb 0.621 0.973-1.046 
WCC 0.083 0.984-1.310 
Platelets 0.343 0.998-1.007 
CRP 0.007* 1.084-1.672 
Albumin 0.861 0.360-2.346 
Age 0.630 0.974-1.045 
Smoking status 0.918 0.123-10.311 
Sex 0.645 0.416-4.126 
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Supplementary Table 2 – Clinical characteristics of individuals for TEM studies of distal 
colon 
Case Age / Sex Clinical Description 
UC 1 23 yrs, Female Active proctitis (UC), Mayo 2 
UC 2 44 yrs; Male Active left sided UC, Mayo 1 
UC 3 41 yrs, Female Active pan-UC, Mayo 2 
UC 4 20 yrs, Male  Active left sided UC, Mayo 2 
UC 5 33 yrs, Male Active severe UC, to point of insertion 
(descending), Mayo 3 
UC 6 49 yrs, Female Active proctitis (UC), Mayo 1 
   
HC 1 56 yrs; Male Investigated for abdominal pain and weight loss; 
normal 
HC 2 45 yrs; Female Investigated for iron deficiency anaemia; internal 
haemorrhoids only 
HC 3 62 yrs, Male Investigated for PR bleeding; sigmoid diverticular 
disease found otherwise normal 
HC 4 55 yrs, Male Investigated for altered bowel habit and family 
history bowel cancer; normal 
HC 5 39 yrs, Female Investigated for iron deficiency anaemia; normal 
HC 6 71 yrs, Male Surveillence scope post polypectomy 2 years ago; 
left sided diverticular disease otherwise normal 
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Supplementary Figure 1:  Correlation between plasma mtDNA (copy/μl) for all samples 
using 2 different primers COXIII and ND2 (n=200, r=0.84, p=<0.0001). 
 
Supplementary Figure 2: Receiver operating characteristic (ROC) analysis of mtDNA, C-
reactive protein and albumin in acute severe UC in-patients and emergency colectomy. 
 
Supplementary Figure 3: Spearman correlation between paired mtDNA plasma (copy/μl) 
and C-reactive protein, serum albumin and white cell count in IBD (n= 180 samples; all 
p<0.0001 with r values of 0.33, -0.32 and 0.37 respectively). CRP – C-reactive protein, WCC 
– white cell count. Median±Interquartile Range (IQR). 
 
Supplementary Figure 4: Representative colonic EM images of 6 UC vs. 6 non-IBD 
individuals. Panel A – UC; Panel B – Non-IBD controls. Black bar - 2μm. Red arrows denote 
damaged mitochondria. 
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